Cahaba Wealth Management’s FibroBiologics FBLG Stock Holding History

Cahaba Wealth Management’s Portfolio FBLG Stock Details FBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-735	Closed	-$3.31K	–	166
2025 Q4	$3.31K	Hold	735	–	–	﹤0.01%	156
2025 Q3	$8.03K	Hold	735	–	–	﹤0.01%	157
2025 Q2	$9.15K	Hold	735	–	–	﹤0.01%	155
2025 Q1	$13.2K	Hold	735	–	–	﹤0.01%	147
2024 Q4	$29.4K	Hold	735	–	–	﹤0.01%	144
2024 Q3	$45.4K	Hold	735	–	–	﹤0.01%	151
2024 Q2	$73.4K	Buy	+735	New	+$140K	0.01%	148

Other funds holding FBLG

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FEG

Fund Evaluation Group Cincinnati, Ohio $3.7B AUM 16.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CFP

Cascade Financial Partners San Diego, California $1.15B AUM 33.6% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

Vanguard Global Advisers Malvern, Pennsylvania $215B AUM

Cahaba Wealth Management's FBLG Position: Q1 2026 in Review

Cahaba Wealth Management sold out of FibroBiologics (FBLG) in Q1 2026, closing a stake of 735 shares — an estimated $3.31K sold.

Cahaba Wealth Management first reported a position in FBLG in Q2 2024 and held it in 7 quarters. The position peaked at $73.4K in Q2 2024. 17 funds tracked by Wall St. Rank hold FBLG as of Q1 2026.

Cahaba Wealth Management reported no remaining FibroBiologics position as of Q1 2026 after selling out during the quarter.
Cahaba Wealth Management sold 735 FibroBiologics shares in Q1 2026, an estimated $3.31K.
Cahaba Wealth Management first reported a position in FibroBiologics in Q2 2024 and held it in 7 quarters.
Cahaba Wealth Management's FibroBiologics position peaked at $73.4K in Q2 2024.
17 funds tracked by Wall St. Rank held FibroBiologics as of Q1 2026.

Based on Cahaba Wealth Management's 13F filing for Q1 2026, filed 29 Apr 2026.